NutraLife BioSciences, Inc.
NLBS
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | 631.90K | 587.50K | 570.80K | 626.70K | 545.60K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 631.90K | 587.50K | 570.80K | 626.70K | 545.60K |
| Cost of Revenue | 515.60K | 538.60K | 569.30K | 543.10K | 327.50K |
| Gross Profit | 116.50K | 49.00K | 1.50K | 83.60K | 218.10K |
| SG&A Expenses | 2.32M | 2.40M | 2.41M | 4.44M | 4.89M |
| Depreciation & Amortization | 229.20K | 201.00K | 168.30K | 114.40K | -4.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.07M | 3.14M | 3.14M | 5.10M | 5.22M |
| Operating Income | -2.43M | -2.55M | -2.57M | -4.47M | -4.67M |
| Income Before Tax | -4.95M | -4.46M | -5.37M | -6.79M | -5.98M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.95 | -4.46 | -5.37 | -6.79 | -5.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.95M | -4.46M | -5.37M | -6.79M | -5.98M |
| EBIT | -2.43M | -2.55M | -2.57M | -4.47M | -4.67M |
| EBITDA | -2.20M | -2.35M | -2.41M | -4.36M | -4.55M |
| EPS Basic | -0.03 | -0.03 | -0.03 | -0.04 | -0.04 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.03 | -0.02 |
| EPS Diluted | -0.03 | -0.03 | -0.03 | -0.04 | -0.04 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.03 | -0.02 |
| Average Basic Shares Outstanding | 695.74M | 687.77M | 674.17M | 661.09M | 637.85M |
| Average Diluted Shares Outstanding | 695.74M | 687.77M | 674.17M | 661.09M | 637.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
